Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 17,813.6	$ 11,819.9	$ 11,370.3
Lipitor ®
Disaggregation of Revenue [Line Items]
Net sales	1,663.2
Norvasc ®
Disaggregation of Revenue [Line Items]
Net sales	824.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	728.5
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	533.8
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	391.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	344.4
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	316.8
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	309.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	284.3
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	226.0
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	299.3
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	201.5
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	185.9
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	168.0
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	$ 161.9